Published in Lancet on September 27, 1980
Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis (1997) 0.90
Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol (1990) 0.89
Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis (1992) 0.87
Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice. Toxicol Appl Pharmacol (2015) 0.81
Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study. Br J Cancer (1984) 0.81
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. J Cancer Res Clin Oncol (1991) 0.80
Ifosfamide chemotherapy for pancreatic carcinoma. Cancer Chemother Pharmacol (1986) 0.79
The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol (1990) 0.79
A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group. Br J Cancer (1993) 0.79
A review of the current status and techniques of allogeneic bone marrow transplantation for treatment of leukaemia. J Clin Pathol (1983) 0.78
Ifosfamide by bolus as treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol (1986) 0.78
The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. Br J Cancer (1994) 0.77
New drugs in respiratory disorders: II. Br Med J (Clin Res Ed) (1983) 0.77
Treatment of small cell lung cancer by pneumonectomy and single course high dose chemotherapy. Thorax (1987) 0.75
Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide. Br J Cancer (1983) 0.75
Cyclophosphamide treatment of systemic lupus erythematosus: risk of bladder cancer exceeds benefit. Br Med J (Clin Res Ed) (1982) 0.75
High-dose ifosfamide and mesna in advanced breast cancer. A phase II study. Cancer Chemother Pharmacol (1990) 0.75
Renal toxicity and chemotherapy in children with cancer Nephrotoxicity and cancer treatment. Br J Clin Pharmacol (2017) 0.75
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem (1995) 3.72
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
In vitro and in vivo radiosensitivity of human tumour cells obtained from a pancreatic carcinoma xenograft. Nature (1976) 2.77
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol (2008) 2.46
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
The synthesis of oligoribonucleotides. IV. Preparation of dinucleoside phosphates from 2',5'-protected ribonucleoside derivatives. Tetrahedron (1968) 2.31
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
A comparison of children affected by prenatal alcohol exposure and attention deficit, hyperactivity disorder. Alcohol Clin Exp Res (1997) 2.13
A colony-forming assay for human tumour xenografts using agar in diffusion chambers. Br J Cancer (1976) 2.11
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res (1995) 2.05
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol (1997) 1.94
Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet (1980) 1.88
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer (2004) 1.87
Survey of treatment of primary breast cancer in Great Britain. Br Med J (Clin Res Ed) (1985) 1.80
Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer (1983) 1.73
Diagnosing breast carcinoma in young women. BMJ (1991) 1.71
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer (2004) 1.69
Palliative chemotherapy for advanced non-small cell lung cancer. BMJ (1994) 1.67
Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol (1991) 1.66
Recurrent Cancer of Head and Neck. Br Med J (1962) 1.63
Isolation and identification of products from alkylation of nucleic acids: ethyl- and isopropyl-purines. Biochem J (1975) 1.62
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol (2005) 1.58
Topical calcipotriol treatment in advanced breast cancer. Lancet (1991) 1.53
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. Eur J Cancer Clin Oncol (1987) 1.51
Reaction products from N-methyl-N-nitrosourea and deoxyribonucleic acid containing thymidine residues. Synthesis and identification of a new methylation product, O4-methylthymidine. Biochem J (1973) 1.50
Breast cancer in adolescents and young women. Eur J Cancer (2003) 1.49
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet (1994) 1.49
Biochemical markers in human breast cancer. Lancet (1977) 1.48
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer (2005) 1.48
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer. Lancet (1995) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
Growth of human tumour cell colonies from biopsies using two soft-agar techniques. Br J Cancer (1978) 1.46
Clinical examination, xeromammography, and fine-needle aspiration cytology in diagnosis of breast tumours. Br Med J (1978) 1.44
The alkylation of 2'-deoxyguanosine and of thymidine with diazoalkanes. Some observations on o-alkylation. Biochem J (1973) 1.43
Physical test for distant metastases in patients with breast cancer. J R Soc Med (1980) 1.42
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab (1993) 1.41
New treatments for advanced cancer: an approach to prioritization. Br J Cancer (2000) 1.41
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol (2009) 1.40
The synthesis of oligoribonucleotides. II. Methoxymethylidene derivatives of ribonucleosides and 5'-ribonucleotides. Tetrahedron (1967) 1.39
Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat (1998) 1.39
Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC). Clin Oncol (R Coll Radiol) (2001) 1.39
Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer (1981) 1.39
Chemical trapping of a reactive metabolite. The metabolism of the AZO-mustard 2'-carboxy-4-di-(2-chloroethyl)amino-2-methylazobenzene. Biochem Pharmacol (1972) 1.38
Effects of prenatal alcohol exposure at school age. I. Physical and cognitive development. Neurotoxicol Teratol (1991) 1.37
Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol (1984) 1.34
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed) (1981) 1.33
Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res (1999) 1.32
Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet (1997) 1.31
In vitro radiation response of cells from four human tumors propagated in immune-suppressed mice. Cancer Res (1978) 1.31
Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol (1974) 1.29
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer (1995) 1.29
Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet (1978) 1.27
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed (1998) 1.27
Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab (1982) 1.25
Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur J Cancer Clin Oncol (1983) 1.25
Alkylation by propylene oxide of deoxyribonucleic acid, adenine, guanosine and deoxyguanylic acid. Biochem J (1972) 1.23
Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer (1991) 1.23
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer (1993) 1.22
Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer (1989) 1.20
Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. Br J Cancer (1979) 1.19
Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol (1994) 1.19
Health-related quality of life in narcolepsy. J Sleep Res (2001) 1.18
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer (2003) 1.18
Effects of prenatal alcohol exposure at school age. II. Attention and behavior. Neurotoxicol Teratol (1991) 1.18
In-vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer. Lancet (1989) 1.18
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol (1998) 1.16
Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem (1995) 1.15
Chemotherapy of human breast-carcinoma xenografts. Br J Cancer (1980) 1.15
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer (1983) 1.15
Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res (1990) 1.15
Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet (1988) 1.15
A controlled trial of cognitive behavioural therapy for non-cardiac chest pain. Psychol Med (1997) 1.15
Factors affecting acute skin toxicity in patients having breast irradiation after conservative surgery: a prospective study of treatment practice at the Royal Marsden Hospital. Clin Oncol (R Coll Radiol) (1996) 1.13
A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol (1992) 1.13
High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol (1979) 1.13
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer (2000) 1.13
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res (1995) 1.12
Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol (1998) 1.10
The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Lung Cancer (2003) 1.10
Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate. Lancet (1987) 1.09
Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin Radiol (1993) 1.09
Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer (1993) 1.08
Identifying high-risk pregnant drinkers: biological and behavioral correlates of continuous heavy drinking during pregnancy. J Stud Alcohol (1987) 1.07
Management of non-cardiac chest pain: from research to clinical practice. Heart (1999) 1.07
3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem (1996) 1.07
Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res (1997) 1.07
Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer (1994) 1.06
Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. Br J Cancer (2006) 1.06